Saturday 17 October 2026
Export ADVB’s income statement to Excel — free account
Advanced Biomed Inc.
ADVB Healthcare Diagnostics & Research
Advanced Biomed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $127,600.00. In the quarter to June 2026, EPS grew 54.8% and free cash flow fell 101.3%, each against the same quarter a year earlier.
3.98
0.90
−18.44%
Follow ADVB
| Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|
P/E ratio |
— | — | 0.90 |
P/S ratio |
— | — | 0.00 |
Altman Z-Score |
— | — | 0.68 |
P/FCF ratio |
— | — | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | 8.58 |
P/Operating CF |
— | — | (9.99) |
P/B ratio |
— | — | 0.47 |
Price to Tangible BV |
— | — | 0.48 |
EV/Sales |
— | — | 0.00 |
EV/EBITDA |
— | — | 0.00 |
EV/Operating CF |
— | — | (2.79) |
EV/FCF |
— | — | (1.20) |
Quick Ratio |
0.95 | 0.00 | 0.26 |
Current Ratio |
1.12 | 1.16 | 9.33 |
Net Debt/EBITDA |
1.22 | 0.03 | 0.06 |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.01 |
Operating CF/Net income |
0.76 | 1.79 | (0.29) |
Capex/Depreciation |
(0.19) | (0.09) | 0.00 |
| 0.00% | (126.79%) | 84.77% | |
| 0.00% | (23.86%) | 36.47% | |
ROIC |
0.00% | (19.70%) | (32.76%) |
Return on Tangible Assets |
(330.01%) | (93.79%) | 54.39% |
Average Days of Receivables |
— | — | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 4,985.27% |
Intangible Assets out of Total Assets |
0.03 | 0.01 | 0.00 |
Share Based Compensation of Revenue |
— | — | 1,750.78% |
Graham Net Nets |
— | — | 2.11 |
Graham Number |
— | — | 33.69 |
Earnings Yield |
— | — | 110.73% |
Free Cash Flow Yield |
— | — | (77.73%) |
Revenue per Share |
0.00 | 0.00 | 0.10 |
Operating CF per Share |
(2.13) | (5.68) | (1.55) |
Capex per Share |
(0.07) | (0.03) | (2.06) |
Free Cash Flow per Share |
(2.20) | (5.71) | (3.61) |
Cash per Share |
2.61 | 0.03 | 0.31 |
Shareholders Equity per Share |
1.66 | 3.39 | 9.80 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
1.66 | 3.39 | 9.80 |
Free Cash Flow |
(2.20) | (5.86) | (4.53) |
Working Capital |
0.32 | 3.14 | 12.28 |
Capital Expenditures |
(0.07) | (0.03) | (2.58) |
Net Current Asset Value |
0.25 | 3.00 | 12.28 |
EV/EBIT |
— | — | 0.00 |
Capex to Sales |
0.00 | 0.00 | 20.23 |
Price to Operating Income |
— | — | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.76 | 1.04 | — |
Cash ROIC |
(51.52%) | (166.92%) | (35.77%) |
Accounts Receivable Turnover |
— | — | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Average Payables |
— | 1.73 | 1.13 |
Average Assets |
— | 13.66 | 18.31 |
Average Common Equity |
— | 2.57 | 7.88 |
Columns are period end dates · fundamentals updated 15 Oct 2026